Hedera
Enabling personalized cancer treatment options through in-house liquid biopsy testing, improving patient outcomes and streamlining treatment monitoring.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | €15.0m | Series A | |
| Total Funding | 000k | ||
Related Content
Hedera Dx is a pioneering startup in the healthcare sector, specifically focusing on cancer diagnostics and treatment optimization through advanced liquid biopsy technology. The company operates in the European market, serving hospitals and medical institutions that require precise and efficient cancer diagnostic tools.
Hedera Dx's primary product is a liquid biopsy assay that uses circulating tumor DNA (ctDNA) extracted from a patient's blood sample. This ctDNA is then analyzed using Next Generation Sequencing (NGS) technology. The company's software generates a clinical report that outlines potential treatment options based on the tumor's genetic profile. This report helps physicians determine the most effective, regulatory-approved therapies for their patients.
The business model of Hedera Dx revolves around providing a comprehensive diagnostic service to hospitals. They make money by charging for the liquid biopsy tests and the accompanying software-generated reports. Their solution is particularly valuable because it simplifies the complex process of ctDNA analysis, ensuring compliance with stringent regulations and improving the efficiency of reporting.
Hedera Dx also contributes to the clinical validation of liquid biopsy technology. They have launched the EMPATHY NSCLC study, the first European, prospective, multicenter clinical validation study for in-house liquid biopsy testing. This study aims to assess the real-world utility and clinical validation of NGS-based liquid biopsies in hospital laboratories.
In summary, Hedera Dx is revolutionizing cancer diagnostics with its innovative liquid biopsy technology, serving hospitals and medical institutions in Europe. Their business model is based on providing diagnostic tests and clinical reports, ensuring regulatory compliance, and contributing to the clinical validation of their technology.
Keywords: liquid biopsy, ctDNA, cancer diagnostics, Next Generation Sequencing, clinical report, treatment optimization, regulatory compliance, hospital laboratories, EMPATHY NSCLC, European market.